PATENT CLAIM ANALYSIS

Application Number: 15905633
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "250000"]

Abstract:
The present invention is directed to a method of simultaneously treating hypertension, hypertriglyceridemia, a pro-inflammatory state, a pro-coagulative state, and insulin resistance (with or without treating obesity or endothelial dysfunction), associated with or independent from Metabolic Syndrome, as well as vascular disease such as cardiovascular, cerebrovascular, or peripheral vascular disease comprising the step of administering to a patient suffering from such disorders a therapeutically effective amount of a central acting dopamine agonist. In one embodiment, the central acting dopamine agonist is bromocriptine, optionally combined with a pharmaceutically acceptable carrier.

Claim (Index 60):
A method of treating endothelial dysfunction in a patient in need of such treatment, comprising the step of:\n (a) administering to a patient identified as suffering from endothelial dysfunction a therapeutically effective amount of between 0.01 and 2.0 mg. per kg per day of a quick release bromocriptine formulation administered at a time of day so as to effectuate peak plasma levels of bromocriptine between 0400 and 1200 hours of the day.

Metadata:
- Claim Count in Document: 167.0
- Percentile: 88.0
- Lexical Diversity: 1.58462
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12154907', '15874430', '13375810', '14506353', '15165485']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6959186257724459
- 35 USC 102 Novelty (BERT): 0.5420487485158264
- Combined Prediction Score: 0.680531638046784
- Mean Citation Score: 290.802608
- Max Citation Score: 371.29193
- Similarity Product: 221.7376563994032

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test